BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2026)
BioXcel Therapeutics (BTAI) posted Amortizatization of Intangibles of $56000.0 for Q1 2026, down 33.33% on a QoQ basis from $84000.0 in Q4 2025, and down 29.11% year-over-year from $79000.0 in Q1 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Amortizatization of Intangibles for 4 years, with the latest figure at $56000.0 in Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 29.11% year-over-year to $56000.0 in Q1 2026; TTM through Jun 2026 was $222000.0, a 29.75% decrease from a year earlier, with the FY2025 full-year figure at $326000.0, up 6.54% from the prior year.
- Amortizatization of Intangibles was $56000.0 for Q1 2026 at BioXcel Therapeutics, down from $84000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $84000.0 in Q4 2025, with the low at $56000.0 in Q1 2026.
- Average Amortizatization of Intangibles over 4 years is $75076.9, with a median of $75000.0 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles advanced 8.0% in 2025, then fell 29.11% in 2026.
- Over 4 years, Amortizatization of Intangibles stood at $74000.0 in 2023, then grew by 6.76% to $79000.0 in 2024, then gained by 6.33% to $84000.0 in 2025, then plunged by 33.33% to $56000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $56000.0 (Q1 2026), $84000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | 1.39 Mn |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 72,000.00 |
| Mar 31, 2023 | 70,000.00 |